Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

NCT07474064 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer (MIBC)

Interventions

DRUG: Probiotic
DRUG: Disitamab Vedotin
DRUG: Toripalimab

Sponsor

chenxu